Goldman Sachs Group Inc Hookipa Pharma Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.27 - $15.0 $33,223 - $392,400	-26,160 Reduced 59.11%	18,093 $24,000
Q3 2022 Nov 10, 2022	SELL	$1.27 - $15.0 $33,223 - $392,400	-26,160 Reduced 59.11%	18,093 $0
Q2 2022 May 14, 2024	BUY	$1.33 - $2.31 $58,856 - $102,224	44,253 New	44,253 $73,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.31 $57,142 - $99,246	-42,964 Reduced 49.26%	44,253 $73,000
Q1 2022 May 16, 2022	BUY	$1.26 - $2.52 $59,431 - $118,863	47,168 Added 117.78%	87,217 $199,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.94 $60,792 - $154,980	26,091 Added 186.93%	40,049 $93,000
Q3 2021 Nov 10, 2021	BUY	$5.89 - $9.35 $82,212 - $130,507	13,958 New	13,958 $82,000

677K

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $98.7M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.